Dräger’s recognition as Frost & Sullivan’s 2025 Global Company of the Year in the respiratory devices industry marks a major milestone in its longstanding commitment to clinical excellence and innovation. This prestigious award honors companies that demonstrate superior strategic execution and measurable impact in global markets, and Dräger has emerged as a clear leader through its unmatched dedication to transforming respiratory care. Evaluated through Frost & Sullivan’s rigorous benchmarking criteria across innovation and customer impact, Dräger earned this top distinction by aligning cutting-edge product development with scalable, patient-centric solutions that improve outcomes in intensive care and high-acuity environments.

The award reflects Dräger’s ability to respond to pressing healthcare challenges with solutions that are both technologically advanced and practically grounded. Its flagship V-Series ventilators, featuring integrated high-flow oxygen therapy, SmartCare/PS, and proportional pressure support, are purpose-built to reduce ventilation times, enhance patient comfort, and lower infection risks. Equally important is Dräger’s expansion into education and digital health support, such as the launch of its Virtuo virtual reality training platform and the revitalized Dräger Academy. These efforts address the growing demand for efficient, scalable training and clinical support in hospitals worldwide, positioning Dräger as a full-spectrum partner in respiratory care delivery.

Looking ahead, Dräger’s award underscores not only past achievements but a strong foundation for future impact. With a focus on secure, interoperable technologies—as shown in its recent Authority to Operate (ATO) certification for ventilator systems by the U.S. Department of Defense—Dräger is prepared to support both civilian and mission-critical healthcare needs globally. By continuing to invest in intelligent automation, digital education, and outcome-driven innovation, Dräger is poised to redefine respiratory care standards while strengthening its role as a trusted global leader in life-saving medical technologies.